CYP2J2 and hepatocellular carcinoma: Specifically, we found in vitro and in vivo that increased Hcy level could promote CYP2J2 expression and EET metabolism via DNA demethylation and the mitogen-activated protein kinase (MAPK) pathway deletion to further increase the risk of HCC.